Prostatic Neoplasms
438
38
69
239
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
86 trials with published results (20%)
Research Maturity
239 completed trials (55% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
13.2%
58 terminated out of 438 trials
80.5%
-6.1% vs benchmark
13%
55 trials in Phase 3/4
36%
86 of 239 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 239 completed trials
Clinical Trials (438)
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Collection of Blood From Patients With Prostate Cancer
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Men at High Genetic Risk for Prostate Cancer
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer